National Cancer Institute National Cancer Institute
U.S. National Institutes of Health National Cancer Institute
NCI Home Cancer Topics Clinical Trials Cancer Statistics Research & Funding News About NCI
NCI Drug Dictionary
Page Options
Print This Page  Print This Page
More NCI Dictionaries
Dictionary of Cancer Terms

Glossary of Statistical Terms

NCI Dictionary of Genetics Terms

Terminology Resources
Quit Smoking Today
Search for
Contains
# A B C D E F G H I J K L M N O P Q R S T U V W X Y Z All

bexarotene  Patient Information
A synthetic retinoic acid agent with potential antineoplastic, chemopreventive, teratogenic and embryotoxic properties. Bexarotene selectively binds to and activates retinoid X receptors (RXRs), thereby inducing changes in gene expression that lead to cell differentiation, decreased cell proliferation, apoptosis of some cancer cell types, and tumor regression. Check for active clinical trials or closed clinical trials using this agent. (NCI Thesaurus)
Synonym:3-methyl TTNEB
US brand name:Targretin
Code name:LGD1069
Chemical structure name:4-[1-(5,6,7,8-tetrahydro-3,5,5,8,8-pentamethyl-2-naphthalenyl)ethenyl]benzoic acid


A Service of the National Cancer Institute
Department of Health and Human Services National Institutes of Health USA.gov